FINWIRES · TerminalLIVE
FINWIRES

Ascendis Pharma's Long-Term Potential Intact, Wedbush Says

By

Ascendis Pharma (ASND) share weakness following its Q2 update was not warranted, as all three commercial products topped consensus revenue estimates and management reiterated long-term revenue targets, Wedbush Securities said in a note Thursday.

The firm sees intact, if not stronger, long-term potential in the company, according to the note.

The brokerage said near-term intellectual property uncertainty around newly launched Yuviwel for achondroplasia likely drove the share decline, but pointed to a strong US launch, with more than 220 unique patient enrollments through July 31, up from over 170 a month earlier.

Wedbush also cited continued growth for Yorvipath, the company's hypoparathyroidism treatment, supported by steady patient demand and a 95% retention rate.

Wedbush maintained its outperform rating on the stock with the price target of $327.

Price: $246.87, Change: $-8.59, Percent Change: -3.36%

Related Articles

Wire

GBM Resources Confirms Continuation of Prospective Gold Host at Queensland Project; Shares Down 5%

GBM Resources (ASX:GBM) confirmed the continuation of the prospective Milled Matrix Breccia host horizon at least 700 meters south of the 309 mineral resource at the Stella prospect, expanding the exploration footprint at the Twin Hills project in Queensland, according to a Thursday filing with the Australian bourse.The company intersected gold mineralization during step-out drilling, with assays returning 8 meters at 1.31 grams per tonne grade of gold from 126 meters, the filing said.Further assays are expected to be released in the next two weeks, per the filing.Shares fell 5% in midday trade Thursday.

ASX:GBM
Wire

Pan American Silver Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

Pan American Silver (PAAS) reported Q2 adjusted earnings late Wednesday of $0.73 per basic share, up from $0.43 a year earlier.Analysts polled by FactSet expected $0.88.Revenue for the quarter ended June 30 rose to $1.12 billion from $812 million a year earlier.Three analysts expected $1.15 billion.The company raised its quarterly dividend to $0.184 a share from $0.18, payable around Sept. 4 to stockholders of record Aug. 24.Pan American Silver shares fell 5.1% in after-hours trading.

$PAAS
Wire

Stantec Q2 Adjusted Earnings, Revenue Rise

Stantec (STN) reported Q2 adjusted earnings late Wednesday of 1.61 Canadian dollars ($1.15) per diluted share, up from CA$1.36 a year earlier.Analysts surveyed by FactSet expected CA$1.58.Net revenue in the three months ended June 30 rose to CA$1.78 billion from CA$1.6 billion a year earlier.Analysts projected CA$1.79 billion.Stantec shares rose 1.3% in after-hours trading.

$STN